Accelerated Approval Strategy

Ocular Therapeutix’s strategic focus on expedited regulatory pathways, addition of clinically meaningful endpoints, and a concentrated, streamlined DR program underscores its effort to bring AXPAXLI to market in 2027, if approved, and to establish a strong position in both wet AMD and diabetic retinopathy.